A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). - Chen HJ; Tu HY; Hu Y; Fan Y; Wu G; Cang S; Yang Y; Yang N; Ma R; Jin G; Xu X; Liu A; et al. (Journal of hematology & oncology, 2025)